Novartis's COPD therapy receives EU recommendation
28 September 2009
Asher Mullard
Please Login to read the full article.
28 September 2009
Asher Mullard
asher.mullard@informa.com
The EU's
CHMP has recommended the approval of
Novartis's indacaterol maleate inhaler (formerly known QAB149) for maintenance bronchodilator treatment of airflow obstruction in adults with chronic obstructive pulmonary disease (COPD). The company plans to launch the drug in the EU, its first market,...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Japanese COPD alliance with Novartis marks new ground for Eisai
- Nycomed to co-market Orion's Easyhaler products in Europe and MENA region
- US FDA delays decision on Novartis COPD drug, giving Forest drug a leap ahead
- US FDA panel backs Novartis lower dose COPD drug, but rejects higher dose
COMMENT
Other Informa Comment
FEATURES
Other Informa Features
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
